ABBOTT INDIA LIMITED
Latest filings
Next results: Thu, 5 Nov · Financial Results- Board meeting set for November 5 to approve Q2 and H1 results · Results
- Routine dematerialization compliance certificate for Jul-Sep 2026 quarter · Compliance
- Newspaper ad on special window for physical share dematerialization · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
A pharmaceuticals company operating in India and the local pharma arm of Abbott Laboratories. It is a pharma-only firm (no medical devices or diagnostics in its Indian operations) that reported Rs 6,929 crore in revenue from operations for FY26, up 8.1% from FY25. Manufacturing is concentrated at a single formulation plant in Goa, supported by 3,467 permanent employees. Recent launches included Extensior (semaglutide) for Type 2 diabetes and Ezybixy for chronic constipation, extending its branded pharma portfolio. Operating costs are spread across materials at 8.9% of revenue, employee costs at 9.7% and other operating expenses at 9.7%, with depreciation at 1.1%. EBITDA for FY26 was Rs 2,180 crore, translating to a 31.46% EBITDA margin, and profit after tax stood at Rs 1,552 crore.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ABBOTT INDIA LIMITED's filed financials and exchange disclosures
What does ABBOTT INDIA LIMITED do?
ABBOTT INDIA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ABBOTINDIA.
Is ABBOTT INDIA LIMITED profitable?
Yes. Over the trailing twelve months ABBOTT INDIA LIMITED reported a net profit of ₹1,552 Cr on revenue of ₹6,929 Cr.
Does ABBOTT INDIA LIMITED pay a dividend?
Yes. The dividend yield is 1.80% at the current price. It paid out 65% of its profit as dividend in FY26.
Is ABBOTT INDIA LIMITED debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹442 Cr of cash.
Is ABBOTT INDIA LIMITED expensive compared with its peers?
On trailing P/E, ABBOTT INDIA LIMITED ranks 95 of 158 in Pharmaceuticals — cheaper than 40% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the ABBOTT INDIA LIMITED share price move in a day?
On a typical session ABBOTT INDIA LIMITED moves 0.73% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are ABBOTT INDIA LIMITED's next results?
Financial Results on Thu, 5 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track ABBOTT INDIA LIMITED's announcements?
Every NSE and BSE filing by ABBOTT INDIA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.